France

The scientific and clinical interest in classical psychedelics in France must be read in the context of broader twentieth‑century psychopharmacology. The modern era began at the pharmaceutical bench in neighbouring Switzerland when Albert Hofmann synthesised lysergic acid diethylamide (LSD) in 1938 and discovered its psychoactive properties in 1943. Sandoz subsequently marketed LSD (as Delysid) from the late 1940s for experimental psychiatry and psychotherapy research, and French psychiatrists and clinical researchers were among the many European investigators who received and experimented with the compound in the 1950s and 1960s. At the same time France was a major centre for discovery in psychopharmacology more generally: French clinicians such as Jean Delay and Pierre Deniker were central to the introduction of antipsychotic therapy (chlorpromazine) in the early 1950s, shaping clinical attitudes to drug‑based psychiatric treatments.

The cultural and regulatory reaction in France mirrored that in other jurisdictions. The countercultural use of psychedelics in the 1960s, international concerns about safety and diversion, and an evolving international drug control regime led to progressively tighter national controls through the 1960s and 1970s. French narcotics legislation (notably legislative frameworks consolidated around 1970) placed LSD, psilocybin, MDMA and related substances under strict criminal control, which substantially limited routine clinical use and constrained publicly funded clinical trials for many decades. Research continued in adjacent areas such as psychopharmacology and neurobiology, but formal clinical investigation of classic psychedelics was modest compared with some other European countries.

From the 1990s onwards there has been a slow re‑awakening of scientific interest in psychedelic compounds internationally, and France has increasingly participated in the modern renaissance since the 2010s. The national regulatory agency (Agence nationale de sécurité du médicament et des produits de santé, ANSM, created in 2012) and research ethics committees now have established pathways for investigator‑initiated clinical trials with controlled substances, and French neuroscience and psychiatry laboratories have contributed mechanistic work (neuroimaging, pharmacology, and safety studies) and engaged in multinational consortia. Nevertheless, the French research landscape retains distinctive features: stronger regulatory caution, a greater emphasis on basic and mechanistic studies and early‑phase trials, and comparatively fewer late‑stage commercial pivotal trials than some neighbouring countries to date.